Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Apr 3:18:1083-1101.
doi: 10.2147/DDDT.S365885. eCollection 2024.

Updated Evaluation of Agalsidase Alfa Enzyme Replacement Therapy for Patients with Fabry Disease: Insights from Real-World Data

Sandro Feriozzi  1 , Cristina Chimenti  2 , Ricardo Claudio Reisin  3
Affiliations
Review

Updated Evaluation of Agalsidase Alfa Enzyme Replacement Therapy for Patients with Fabry Disease: Insights from Real-World Data

Sandro Feriozzi et al. Drug Des Devel Ther. .

Abstract

The clinical use of agalsidase alfa as enzyme replacement therapy (ERT) for Fabry disease (FD) has spread since 2001, and a large body of evidence of its effectiveness has been collected. This review presents the clinical and laboratory results achieved with agalsidase alfa, which has been published in the literature. Agalsidase alfa infusion slows down or stops the progression of renal damage, expressed by reduction or stabilization of the annual decline of the glomerular filtration rate; yearly decrease of glomerular filtration rate (slope) sometimes is reduced until its stabilization. ERT prevents or reduces the occurrence of hypertrophic cardiomyopathy or slows the increase over time if it is already present. Moreover, regarding neurological manifestations, ERT improves neuropathic pain and quality of life, and recent data indicated that it may also prevent the burden of cerebrovascular disease. In addition to ERT's clinical benefits, crucial topics like the most appropriate time to start therapy and the role of anti-drug antibodies (ADA) are analyzed. Treatment with agalsidase alfa in patients with FD substantially improves their outcomes and enhances their quality of life in patients with FD.

Keywords: Fabry disease; agalsidase alfa; clinical outcome in Fabry treated patients; enzyme replacement therapy.

PubMed Disclaimer

Conflict of interest statement

Sandro Feriozzi has received travel assistance and honoraria for lecturing and participating in advisory boards from Sanofi, Takeda, Otsuka and Amicus. Cristina Chimenti has received travel assistance and honoraria for lecturing and participating in Pfizer, Sanofi, Alnylam, Takeda, and Amicus advisory boards. Ricardo Claudio Reisin has received travel assistance and honoraria for lecturing and participating in advisory boards from Sanofi, Takeda, PTC, Astra Zeneka, Pfizer and CSL Behring. The authors report no other conflicts of interest in this work.

References

    1. Germain DP. Fabry disease. Orphanet J Rare Dis. 2010;5(1):30. doi:10.1186/1750-1172-5-30 - DOI - PMC - PubMed
    1. Arends M, Wanner C, Hughes D, et al. Characterization of Classical and Nonclassical Fabry Disease: a Multicenter Study. J Am Soc Nephrol. 2017;28(5):1631–1641. doi:10.1681/ASN.2016090964 - DOI - PMC - PubMed
    1. Umer M, Kalra DK. Treatment of Fabry Disease: established and Emerging Therapies. Pharmaceuticals. 2023;16(2):320. doi:10.3390/ph16020320 - DOI - PMC - PubMed
    1. Schiffman R, Hughes D, Linthorst GE, et al. Screening, diagnosis, and management of patients with Fabry disease: conclusions from a Kidney Disease: improving Global Outcomes(KDIGO). Controversies Conferences Kidney Int. 2017;91(2):284–293. doi:10.1016/j.kint.2016.10.004 - DOI - PubMed
    1. Beck M, Ramaswami U, Hernberg-Stahl E, et al. Twenty years of the Fabry Outcome Survey(FOS): insights, achievements, and lessons learned from a global patient registry. Orphanet J Rare Diseases. 2022;17:238. doi:10.1186/s13023-022-02392-9 - DOI - PMC - PubMed